Glomerulonephritis Market Report 2026

The glomerulonephritis market size has grown steadily in recent years. It will grow from $11.61 billion in 2025 to $12.18 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to prevalence of autoimmune disorders, kidney biopsy adoption, growth of nephrology clinics, availability of immunosuppressive drugs, diagnostic laboratory expansion.

The glomerulonephritis market size is expected to see steady growth in the next few years. It will grow to $14.66 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advances in renal diagnostics, precision nephrology development, increased chronic kidney disease prevalence, expansion of specialty nephrology care, improved treatment adherence. Major trends in the forecast period include increased focus on early kidney disease diagnosis, rising use of immunosuppressive therapies, growing adoption of biomarker-based testing, expansion of dialysis support services, improved chronic disease management.

The rising prevalence of kidney disorders is expected to drive the growth of the glomerulonephritis market in the coming years. Kidney disorders encompass a range of conditions affecting the structure or function of the kidneys, leading to impaired filtration, waste removal, and fluid balance. The increase in kidney disorders is attributed to factors such as aging populations, higher rates of chronic diseases like diabetes and hypertension, and lifestyle factors. These disorders contribute to glomerulonephritis by causing immune system dysfunction, chronic inflammation, or structural damage, which impairs kidney filtration and function. For instance, in June 2023, Kidney Research UK, a UK-based charitable organization, reported that approximately 7.19 million people in the UK were affected by chronic kidney disease in 2023 - over 10% of the population - with projections estimating this number to rise to 7.61 million by 2033. Therefore, the increasing prevalence of kidney disorders is driving the growth of the glomerulonephritis market.

Leading companies in the glomerulonephritis market are focusing on developing advanced non-immunosuppressive treatments to meet unmet medical needs and improve patient outcomes. Non-immunosuppressive therapies treat conditions without weakening the immune system, providing effective care while preserving immune function. For example, in September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, introduced FILSPARI (sparsentan), approved by the FDA for treating IgA nephropathy, a kidney disease. FILSPARI is the only non-immunosuppressive therapy shown to significantly slow kidney function decline in these patients. This approval represents a major advancement in treating IgA nephropathy, the most common form of primary glomerulonephritis, and offers a new option for patients who previously had limited treatment choices. It underscores Travere’s commitment to improving outcomes for kidney disease patients.

In May 2023, Rona Therapeutics Inc., a China-based biopharmaceutical company, partnered with Keymed Biosciences Inc. to address the urgent need for new therapies. This collaboration aims to develop first-in-class siRNA therapeutics for glomerulonephritis. Keymed Biosciences Inc., also based in China, specializes in developing treatments for glomerulonephritis.

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., Chinook Therapeutics, Purespring Therapeutics, Walden Biosciences, Visterra Inc.

North America was the largest region in the glomerulonephritis market in 2025. The regions covered in the glomerulonephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glomerulonephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the glomerulonephritis market by increasing costs of imported diagnostic reagents, dialysis equipment, and specialty medications. Hospitals and nephrology clinics are most affected due to reliance on imported supplies. These tariffs raise treatment costs by increasing expenses for diagnostic evaluation, immunosuppressive therapy, and renal support. However, they encourage domestic renal care manufacturing, strengthening local production of dialysis equipment and nephrology drugs.

The glomerulonephritis market research report is one of a series of new reports that provides glomerulonephritis market statistics, including glomerulonephritis industry global market size, regional shares, competitors with a glomerulonephritis market share, detailed glomerulonephritis market segments, market trends and opportunities, and any further data you may need to thrive in the glomerulonephritis industry. This glomerulonephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glomerulonephritis is a kidney disorder marked by inflammation of the glomeruli, the small filters in the kidneys responsible for removing waste and excess fluids from the blood. It can result from infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in the urine, proteinuria, and swelling. If left untreated, it may progress to chronic kidney disease or kidney failure.

The main types of glomerulonephritis are acute glomerulonephritis and chronic glomerulonephritis. Acute glomerulonephritis is a sudden inflammation of the kidneys, often triggered by infections, and requires prompt treatment to prevent long-term damage. Diagnosis involves various tests, including urine and blood tests, imaging studies, kidney biopsy, and others. Treatments include medications, surgery, dialysis, and other interventions. These treatments are distributed through hospital pharmacies, retail pharmacies, and other channels, and are used by hospitals, specialty clinics, and other healthcare providers.

The glomerulonephritis market consists of revenues earned by entities by providing services such as immunosuppressive therapy, blood pressure control, and kidney transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The glomerulonephritis market also includes sales of complement-level test kits, urine protein test kits, and medication. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.